{"nctId":"NCT00293254","briefTitle":"A Study to Evaluate the Safety and Efficacy of Raltegravir (MK0518) in HIV-Infected Patients Failing Current Antiretroviral Therapies (0518-019)","startDateStruct":{"date":"2006-02"},"conditions":["HIV Infections"],"count":351,"armGroups":[{"label":"1","type":"EXPERIMENTAL","interventionNames":["Drug: raltegravir potassium"]},{"label":"2","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Comparator: placebo"]}],"interventions":[{"name":"raltegravir potassium","otherNames":["ISENTRESSâ„¢"]},{"name":"Comparator: placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Patient must be HIV positive with HIV RNA values that are within ranges required by the study\n* Patient must have documented failure of certain antiretroviral therapy\n* Patient must be on the same antiretroviral therapy for at least the past two months\n\nExclusion Criteria:\n\n* Patient less than 16 years old\n* Additional study criteria will be discussed and identified by the study doctor","healthyVolunteers":false,"sex":"ALL","minimumAge":"16 Years","stdAges":["CHILD","ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Percentage of Participants Achieving HIV RNA <400 Copies/mL at Week 16","description":"Percentage of participants who achieved HIV RNA \\<400 copies/mL at Week 16","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"77.3","spread":null},{"groupId":"OG001","value":"42.9","spread":null}]}]}]},{"type":"PRIMARY","title":"Percentage of Participants Achieving HIV RNA <400 Copies/mL at Week 48","description":"Percentage of participants who achieved HIV RNA \\<400 copies/mL at Week 48","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"71.1","spread":null},{"groupId":"OG001","value":"37.8","spread":null}]}]}]},{"type":"PRIMARY","title":"Double-Blind Extension - Week 156: Percentage of Participants Achieving HIV RNA <400 Copies/mL","description":"Percentage of participants who achieved HIV RNA \\<400 copies/mL at Week 156","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"50.2","spread":null},{"groupId":"OG001","value":"21.0","spread":null}]}]}]},{"type":"PRIMARY","title":"Open-Label Extension - Week 240: Percentage of Participants Achieving HIV RNA <400 Copies/mL","description":"Percentage of participants who achieved HIV RNA \\<400 Copies/mL at Week 240","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"45.7","spread":null},{"groupId":"OG001","value":"13.4","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Achieving HIV RNA <50 Copies/mL at Week 16","description":"Percentage of participants who achieved HIV RNA \\<50 copies/mL at Week 16","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"62.0","spread":null},{"groupId":"OG001","value":"36.1","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Achieving HIV RNA <50 Copies/mL at Week 48","description":"Percentage of participants who achieved HIV RNA \\<50 copies/mL at Week 48","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"59.6","spread":null},{"groupId":"OG001","value":"34.5","spread":null}]}]}]},{"type":"SECONDARY","title":"Double-Blind Extension - Week 156: Percentage of Participants Achieving HIV RNA <50 Copies/mL","description":"Percentage of participants who achieved HIV RNA \\<50 copies/mL at Week 156","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"47.6","spread":null},{"groupId":"OG001","value":"17.6","spread":null}]}]}]},{"type":"SECONDARY","title":"Open-Label Extension - Week 240: Percentage of Participants Achieving HIV RNA <50 Copies/mL","description":"Percentage of participants who achieved HIV RNA \\<50 copies/mL at Week 240","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"41.3","spread":null},{"groupId":"OG001","value":"13.4","spread":null}]}]}]},{"type":"SECONDARY","title":"Double-Blind Extension - Week 156: Percentage of Participants Without Loss of Virologic Response","description":"For participants with confirmed HIV RNA levels \\<50 copies/mL on 2 consecutive visits, loss of virologic response is the occurrence of the first value \\>50 copies/mL or loss to follow-up; participants who never achieved HIV RNA \\<50 copies/mL on 2 consecutive visits are also considered as having loss of virologic response. Events are the numbers of participants with loss of virologic response versus the numbers of participants with no loss of virologic response (event-free).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"44.3","spread":null},{"groupId":"OG001","value":"17.6","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in HIV RNA (Log 10 Copies/mL) at Week 16","description":"Mean change from baseline at Week 16 in HIV RNA (log 10 copies/mL)","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.92","spread":null},{"groupId":"OG001","value":"-1.06","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in HIV RNA (log10 Copies/mL) at Week 48","description":"Mean change from baseline at Week 48 in HIV RNA (log10 copies/mL)","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.75","spread":null},{"groupId":"OG001","value":"-0.87","spread":null}]}]}]},{"type":"SECONDARY","title":"Double-Blind Extension - Week 156: Change From Baseline in HIV RNA (log10 Copies/mL)","description":"Mean change from baseline at Week 156 in HIV RNA (log10 copies/mL)","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.37","spread":null},{"groupId":"OG001","value":"-0.52","spread":null}]}]}]},{"type":"SECONDARY","title":"Open-Label Extension - Week 240: Change From Baseline in HIV RNA (log10 Copies/mL)","description":"Mean change from baseline at Week 240 in HIV RNA (log10 copies/mL)","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.31","spread":null},{"groupId":"OG001","value":"-0.41","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in CD4 Cell Count (Cells/mm^3) at Week 16","description":"Mean change from baseline at Week 16 in CD4 cell count (cells/mm\\^3)","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"85.8","spread":null},{"groupId":"OG001","value":"39.9","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in CD4 Cell Count (Cells/mm^3) at Week 48","description":"Mean change from baseline at Week 48 in CD4 cell count (cells/mm\\^3)","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"98.4","spread":null},{"groupId":"OG001","value":"39.8","spread":null}]}]}]},{"type":"SECONDARY","title":"Double-Blind Extension - Week 156: Change From Baseline in CD4 Cell Count(Cells/mm^3)","description":"Mean change from baseline at Week 156 in CD4 cell count (cells/mm\\^3)","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"157.2","spread":null},{"groupId":"OG001","value":"54.2","spread":null}]}]}]},{"type":"SECONDARY","title":"Open-Label Extension - Week 240: Change From Baseline in CD4 Cell Count (Cells/mm^3)","description":"Mean change from baseline at Week 240 in CD4 cell count (cells/mm\\^3)","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"172.1","spread":null},{"groupId":"OG001","value":"54.1","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":80,"n":230},"commonTop":["Diarrhoea","Upper respiratory tract infection","Nausea","Fatigue","Headache"]}}}